ArticleCell cycle (Georgetown, Tex.)2019
Differentiation of equine induced pluripotent stem cells into mesenchymal lineage for therapeutic use.
Article in Cell cycle (Georgetown, Tex.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Derivation of Equine Mesenchymal Stem/Stromal Cells from Induced Pluripotent Stem Cells via the Neural Crest Pathway and Characterisation by Immunophenotype and Tri-Lineage Differentiation.Animals : an open access journal from MDPI · 2026Article
- Impact of differentiation protocols on the functionality of mesenchymal stem cells derived from induced pluripotent stem cells.World journal of stem cells · 2025Article
- Generation of equine induced pluripotent stem cells from cells of embryonic, perinatal and adult tissues.Stem cell research & therapy · 2025Article
- Human induced neural progenitor cells generated from three-dimensional aggregate-based culture significantly improve post-stroke recovery in tMCAO mice.Stem cell research & therapy · 2025Article
- Footprint-free induced pluripotent stem cells can be successfully differentiated into mesenchymal stromal cells in the feline model.Stem cell research & therapy · 2025Article
- Effect of hypoxia on proliferation and differentiation of induced pluripotent stem cell-derived mesenchymal stem cells.Heliyon · 2024Article
- Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies.ACS pharmacology & translational science · 2024Review
- Mechanisms of Embryonic Stem Cell Pluripotency Maintenance and Their Application in Livestock and Poultry Breeding.Animals : an open access journal from MDPI · 2024Review
- Early Osteogenic-Induced Adipose-Derived Stem Cells and Canine Bone Regeneration Potential Analyzed Using Biodegradable Scaffolds.Bioengineering (Basel, Switzerland) · 2023Article
- Mesenchymal Stem Cells Isolated from Equine Hair Follicles Using a Method of Air-Liquid Interface.Stem cell reviews and reports · 2023Article
- Potential and Limitations of Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells in Musculoskeletal Disorders Treatment.Biomolecules · 2023Review
- iPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams.Biomedicines · 2021Review
- Mesenchymal Stem Cell and MicroRNA Therapy of Musculoskeletal Diseases.International journal of stem cells · 2021Review
- A Review of OCT4 Functions and Applications to Equine Embryos.Journal of equine veterinary science · 2021Review
- The use of induced pluripotent stem cells in domestic animals: a narrative review.BMC veterinary research · 2020Review
- Induced pluripotent stem cells from farm animals.Journal of animal science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In previous work, we established an equine induced pluripotent stem cell line (E-iPSCs) from equine adipose-derived stem cells (ASCs) using a lentiviral vector encoding four transcription factors: Oct4, Sox2, Klf4, and c-Myc. In the current study, we attempted to differentiate these established E-iPSCs into mesenchymal stem cells (MSCs) by serial passaging using MSC-defined media for stem cell expansion. Differentiation of the MSCs was confirmed by analyzing expression levels of the MSC surface markers CD44 and CD29, and the pluripotency markers Nanog and Oct4. Results indicated that the E-iPSC-derived MSCs (E-iPSC-MSCs) retained the characteristics of MSCs, including the ability to differentiate into chondrogenic, osteogenic, or myogenic lineages. E-iPSC-MSCs were rendered suitable for therapeutic use by inhibiting immune rejection through exposure to transforming growth factor beta 2 (TGF-β2) in culture, which down-regulated the expression of major histocompatibility complex class I (MHC class I) proteins that cause immune rejection if they are incompatible with the MHC antigen of the recipient. We reported 16 cases of E-iPSC-MSC transplantations into injured horses with generally positive effects, such as reduced lameness and fraction lines. Our findings indicate that E-iPSC-MSCs can demonstrate MSC characteristics and be safely and practically used in the treatment of musculoskeletal injuries in horses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.